MiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• MiMedx Group has a “Moderate Buy” consensus rating from seven analysts: six rate it a buy and one rates it a sell. The average 12-month price target is $8.57, versus a recent share price of $4.55.
• The company’s latest quarterly results matched expectations, with a loss of $0.05 per share and revenue of $64.36 million, slightly above analyst estimates of $63.46 million.
• Institutional investors own approximately 79.15% of the stock, with BlackRock, Nantahala Capital Management and Paradigm Capital among firms that recently established or increased positions.

MiMedx Group, Inc (NASDAQ:MDXG - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $8.57.

A number of brokerages have issued reports on MDXG. Raymond James Financial set a $8.00 price target on shares of MiMedx Group in a report on Monday, August 17th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of MiMedx Group in a report on Tuesday, September 15th. Weiss Ratings upgraded MiMedx Group from a "sell (d)" rating to a "sell (d+)" rating in a research report on Thursday, August 27th. Seaport Research Partners lowered MiMedx Group to a "neutral" rating in a research note on Monday, August 17th. Finally, Wall Street Zen raised MiMedx Group from a "sell" rating to a "hold" rating in a research note on Saturday, August 29th.

MiMedx Group Price Performance

Shares of MiMedx Group stock opened at $4.55 on Tuesday. The company has a market capitalization of $663.21 million, a price-to-earnings ratio of 113.78 and a beta of 1.18. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07. The stock's 50-day simple moving average is $4.48 and its 200-day simple moving average is $4.04. MiMedx Group has a 52 week low of $3.03 and a 52 week high of $7.97.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $64.36 million during the quarter, compared to analysts' expectations of $63.46 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. As a group, analysts expect that MiMedx Group will post -0.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MiMedx Group

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of MiMedx Group in the 2nd quarter worth about $46,795,000. Nantahala Capital Management LLC purchased a new stake in MiMedx Group in the 2nd quarter worth about $18,355,075. Paradigm Capital Management Inc. NY purchased a new stake in MiMedx Group in the 2nd quarter worth about $15,681,000. Renaissance Technologies LLC lifted its stake in MiMedx Group by 22.4% in the first quarter. Renaissance Technologies LLC now owns 3,019,871 shares of the company's stock worth $11,928,000 after purchasing an additional 552,806 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in MiMedx Group by 8.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,694,002 shares of the company's stock worth $10,640,000 after purchasing an additional 214,633 shares during the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc is a regenerative healthcare company that develops, manufactures and markets human placental tissue allografts and related biomaterial products. Its products are derived from donated human placental tissue and are processed for use in healthcare settings, including wound care, surgery and orthopedic applications.

The company's portfolio includes tissue allografts such as EPIFIX, EPIEFFECT, GRAFIX and AMNIOFIX. These products are designed to support the management of chronic and acute wounds, surgical reconstruction and other clinical procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.